By Paul Tullis — 2021
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Read on www.nature.com
CLEAR ALL
The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.
1
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.
Amazonian healing traditions collide with Western medical sensibilities.
2
A new generation of research into psilocybin could change how we treat numerous mental health conditions.
In a recent UK trial, 12 patients with major depression took a pill quite different to commonly prescribed antidepressants: 25mg of psilocybin, the psychedelic compound found in magic mushrooms.
At Imperial College we’ve been comparing psilocybin to conventional antidepressants—and the results are likely to be game-changing.
The mind-altering drug has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.
My first encounter with ketamine did not go well.
A single dose of psilocybin, a compound found in “magic mushrooms,” provides long-term relief of anxiety and depression in cancer patients, a new study finds.
3
The new research looked at cancer patients who took part in a study nearly five years ago.